AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Tg Therapeutics 15min chart shows MACD Death Cross, Bollinger Bands Narrowing.
ByAinvest
Monday, Sep 22, 2025 3:05 pm ET1min read
According to the technical analysis of Tg Therapeutics' 15-minute chart, a MACD Death Cross and narrowing Bollinger Bands have been observed as of September 22, 2022 at 15:00. This indicates that the stock price is likely to experience further downward momentum, with a decreasing magnitude of price fluctuations.
According to recent reports, B. Riley Securities has maintained its Buy rating for TG Therapeutics (TGTX) and raised the price target from $53.00 to $55.00, reflecting a 3.77% increase [1]. The analyst responsible for this update, Mayank Mamtani, suggests that the increase aligns with recent market evaluations and strategic company developments. TG Therapeutics, a biopharmaceutical company focused on B-cell diseases, continues to be seen favorably within the market.The company has received FDA approval for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) and is developing several promising drugs, including TG-1701, Azer-Cel, and TG-1801, for B-cell disorders [1]. Geographically, TG Therapeutics generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Based on Wall Street analysts' forecasts, the average target price for TG Therapeutics is $42.00, with a high estimate of $55.00 and a low estimate of $11.00. The consensus recommendation from 9 brokerage firms is "Outperform," indicating a positive outlook for the company [1].
Investors in TG Therapeutics have also been observing new options trading for the May 2026 expiration. A put contract at the $32.00 strike price has a current bid of $5.80, representing a potential yield boost of 18.12% if the contract expires worthless. Meanwhile, a call contract at the $34.00 strike price has a current bid of $6.30, offering a potential yield boost of 19.10% [2].
Technical analysis of TG Therapeutics' 15-minute chart indicates a MACD Death Cross and narrowing Bollinger Bands as of September 22, 2022 at 15:00, suggesting further downward momentum with decreasing price fluctuations .
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet